The trial sponsored by G1 Therapeutics for Trilaciclib in ES-SCLC patients may have a positive impact on the company's stock price, as successful trials can lead to increased investor confidence and potential revenue growth from the drug's sales. The trial is not yet recruiting, so the impact may not be immediate, but it is still relevant and important for investors to consider.